IMPROVE-IT: Scenarios for understanding the results
3' education - Sep. 9, 2014 - Barcelona - Prof Chris Packard
Prof. Chris Packard (Glasgow) reviews the potential implications of new LDL-c lowering clinical trial outcomes for ezetimibe and new therapeutic options such as PCSK9 inhibitors
Share this page with your colleagues and friends: